Introduction to the official launch time and approval progress of filgotinib

Filgotinib is a selective JAK1 inhibitor mainly used to treat moderately to severely active rheumatoid arthritis and other inflammatory diseases. Its unique pharmacological mechanism makes it a potential drug for the treatment of autoimmune diseases, and has attracted much attention from the global pharmaceutical community. Currently, filgotinib is in different stages of approval in many countries and regions and has not yet been officially approved for marketing in mainland China.

In the international market, filgotinib has been approved in Europe and other regions for the treatment of specific indications. Relevant pharmaceutical companies continue to advance registration applications in many countries around the world, hoping to expand their market coverage and benefit patients. Due to the complex and strict drug approval process, which involves clinical trial data review, drug safety assessment and quality control, the approval progress of filgotinib in China is relatively slow and is still in the application or waiting for approval stage.

Currently, if domestic patients need to use filgotinib, they mainly rely on imported drugs or overseas drug purchase channels. The European version of the original drug is more expensive, with a box (200mg and 30tablets) priced at more than 10,000 yuan, which brings a greater financial burden to patients. At the same time, there are also imitation versions produced by Laos Lucius and other manufacturers on the market, which are relatively cheap. A box (100mg30tablets) sells for about 900 yuan, but patients should pay attention to the quality of the medicine and legal channels when purchasing.

Overall, it will take time for filgotinib to be officially launched in China, and relevant approvals are still progressing steadily. In the future, with the continuous improvement of clinical data and the strengthening of policy support, it is expected that filgotinib will be approved for marketing in China, providing new treatment options for more patients. At the same time, prices are expected to be reasonably controlled through the introduction of generic drugs and the improvement of medical insurance policies, reducing patients' financial pressure and improving drug accessibility.

Reference materials:https://www.drugs.com/

xa0